Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

ClinicalTrials.gov ID: NCT00050232

Public ClinicalTrials.gov record NCT00050232. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT00050232
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Avanir Pharmaceuticals
Industry
Enrollment
96 participants

Conditions and interventions

Interventions

  • AVP-923 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 68 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2002
Primary completion
May 31, 2004
Completion
May 31, 2004
Last update posted
Jul 13, 2016

2002 – 2004

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Barrow Neurological Institute Phoenix Arizona 85013
George Washington University Medical Faculty Associates Washington D.C. District of Columbia 20037
Neurological Associates Fort Lauderdale Florida 33334
Neurology & Headache Specialist of Atlanta, L.L.C. Decatur Georgia 30033
Radiant Research Alexian Brothers Elk Grove Village Illinois 60007
Consultants in Neurology LTD Northbrook Illinois 60062
Advanced Neurology Specialists Great Falls Montana 59405
Neurological Associates, P.C. Lincoln Nebraska 68506
Upstate Clinical Research Albany New York 12205
DENT Neurologic Group L.L.P. Amherst New York 14266
Hospital for Joint Diseases - MS Care Center New York New York 10003
Institute for Human Performance Syracuse New York 13210
Raleigh Neurology Associates, P.A. Raleigh North Carolina 27607
NeuroCare Center, Inc. Canton Ohio 44718
Leheigh Valley Neurosciences and Pain Research Center Allentown Pennsylvania 18103
Westmorland Neurology Greensburg Pennsylvania 15601
Neurological Associates of Delaware Valley Upland Pennsylvania 19013
FACH-UHC Department of Neurological Services Burlington Vermont 05401
Swedish Medical Center Seattle Washington 98122
Neurology and Neurosurgery Associates of Tacoma Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00050232, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 13, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00050232 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →